Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 10/20 | 0.54 |
| ▸ | EED | O75530 | 5/20 | 0.54 |
| ▸ | RBBP4 | Q09028 | 5/20 | 0.54 |
| ▸ | SUZ12 | Q15022 | 5/20 | 0.54 |
| ▸ | RBBP7 | Q16576 | 5/20 | 0.54 |
| ▸ | AEBP2 | Q6ZN18 | 3/20 | 0.54 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.47 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.46 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12684231 | 0.86 | EZH2 (0.73) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL19391448 | 0.77 | EZH2 (0.46) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12683928 | 0.76 | EZH2 (0.73) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL20170042 | 0.76 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL20170326 | 0.75 | EZH2 (0.45) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL18800359 | 0.74 | EZH2 (0.49) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL16545665 | 0.74 | EZH2 (0.66) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL21285038 | 0.74 | EZH2 (0.64) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL22604767 | 0.74 | EZH2 (0.67) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL19657083 | 0.73 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885RBBP4 2047/4885 |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885RBBP4 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.